Gilead Sciences' Hepatitis Drug in Spotlight


"Both medical and investor communities will scrutinize results from an experimental, next-generation treatment for the liver-destroying virus hepatitis C."

Minyanville, Brett Chase

It's just about showtime for Gilead Sciences Inc. (GILD:NASDAQ) and its experimental hepatitis C drug.

When specialist doctors from around the world gather in Spain next week to learn about new drugs in development for liver diseases, data for Gilead's GS-7977 will be closely scrutinized and among the most anticipated research presented. The company hopes to show it has a real potential winner of a drug to treat the liver-wasting virus hepatitis C.

The big medical meeting, the International Liver Conference, begins Wednesday, and some scientific abstracts have been released in advance of the five-day gathering. However, a pair of key studies for Gilead's drug are still embargoed until presentations starting Thursday. Gilead and a host of rivals are trying to develop an all-oral and better treatment regimen for hepatitis C. There has been a lot of excitement in the medical community and the investment world over Gilead's drug. . .View Full Article

Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe